In the past six months, Eli Lilly has launched three major artificial-intelligence programs designed to transform its R&D engine. In September it rolled out TuneLab, an AI-driven drug discovery platform offered at no cost to smaller biotech firms in exchange for anonymized data sets that will enrich Lilly’s proprietary models. In October, the company formed a strategic partnership with Nvidia to co-develop what it describes as the most powerful AI supercomputer in the pharmaceutical sector, driven by over 5,000 latest-generation GPUs and capable of running molecular simulations at unprecedented speed. Earlier this month, Lilly and Nvidia broke ground on a joint AI discovery lab in the San Francisco Bay Area, where cross-functional teams will apply deep learning to reduce candidate screening times by an estimated 30 to 40 percent. If successful, these AI initiatives could shorten average development timelines for Phase I to Phase III candidates from roughly eight years to as few as five, potentially lowering R&D spend by as much as $1.5 billion per major program over the next decade.

In late December, Eli Lilly submitted its oral GLP-1 therapy, orforglipron, to the U.S. FDA following positive Phase III results showing average weight loss of 10.8 percent at 36 weeks in patients with type 2 diabetes. The agency initially granted a priority review voucher, targeting a decision by the end of February, but has since extended its review period, setting a new action date of April 10, 2026. This six-week delay gives Novo Nordisk’s already-approved oral GLP-1 drug additional time to entrench supply chains and prescriber relationships. However, analysts note orforglipron’s superior glycemic-control data and differentiated safety profile, which could allow Lilly to recoup any first-mover disadvantage and capture an estimated 25 to 30 percent share of the oral GLP-1 market within two years of launch.

Third-quarter 13F filings show that First Citizens Bank & Trust increased its Eli Lilly stake by 58.8 percent, acquiring 9,121 shares to bring its total to 24,634 shares valued at $18.8 million. Meanwhile, Commerzbank Aktiengesellschaft trimmed its position by 1.8 percent, reducing holdings by 741 shares to 39,787 shares worth $30.4 million. Smaller managers such as Evolution Wealth Management, Sumitomo Mitsui Financial Group and Bare Financial Services opened new positions ranging from $27,000 to $31,000. Collectively, institutional investors now own over 82 percent of Lilly’s outstanding shares, underscoring confidence in the company’s long-term growth prospects despite near-term regulatory timing shifts.